Biotech Values

[DewDiligence]

Re: OCRX /Xifaxan combination therapy

One other noteworthy tidbit from OCRX's Stifel webcast is that OCRX thinks the STOP-HE trial will address the issue of whether OCR-002 works in combination with Xifaxan, and hence OCRX need not conduct combination studies per se.

Although STOP-HE does not require Xifaxan use, it permits Xifaxan to be used in the SoC arm at the discretion of the investigator. Given Xifaxan's popularity as an off-label treatment in acute HE, STOP-HE should thus produce an ample amount of data on patients who receive both drugs.